Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: The KID study

Haematologica

Volumn 101, Issue 6, 2016, Pages 717-723

  Lee, Sung Eun ^a   Choi, Soo Young ^a   Song, Hye Young ^a   Kim, Soo Hyun ^a   Choi, Mi Yeon ^a   Park, Joon Seong ^b   Kim, Hyeoung Joon ^c   Kim, Sung Hyun ^d   Zang, Dae Young ^e   Oh, Sukjoong ^f   Kim, Hawk ^g   Do, Young Rok ^h   Kwak, Jae Yong ⁱ   Kim, Jeong A ^j   Kim, Dae Young ^k   Mun, Yeung Chul ^l   Lee, Won Sik ^m   Chang, Myung Hee ⁿ   Park, Jinny ^o   Kwon, Ji Hyun ^p   Kim, Dong Wook ^a,q   more..

^a The Catholic University of Korea   (South Korea)

^b Ajou University School of Medicine   (South Korea)

^c Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^d Dong A University College of Medicine   (South Korea)

^e Hallym University College of Medicine   (South Korea)

^f Sungkyunkwan University   (South Korea)

^g Ulsan University College of Medicine   (South Korea)

^h Keimyung University   (South Korea)

ⁱ Chonbuk National University Medical School   (South Korea)

^j The Catholic University of Korea   (South Korea)

^k University of Ulsan College of Medicine   (South Korea)

^l Ewha Womans University School of Medicine   (South Korea)

^m Inje University College of Medicine   (South Korea)

ⁿ National Health Insurance Corporation   (South Korea)

^o Gachon University College of Medicine   (South Korea)

^p Chungbuk National University Hospital   (South Korea)

^q The Catholic University of Korea   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MAJOR MOLECULAR RESPONSE; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MUSCULOSKELETAL PAIN; POLYMERASE CHAIN REACTION; PRURITUS; QUESTIONNAIRE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; TREATMENT WITHDRAWAL; VERY ELDERLY; WITHDRAWAL SYNDROME; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASM, RESIDUAL; PROGNOSIS; RECURRENT DISEASE; RETREATMENT; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; HUMANS; IMATINIB MESYLATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECURRENCE; RETREATMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 84971570003     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.139899     Document Type: Article

References (21)

1. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029-1035.
2. Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32(5):424-430.
3. Lee SE, Choi SY, Bang JH, et al. Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib. Am J Hematol. 2013;88(6): 449-454.
4. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515-522.
5. Thielen N, van der Holt B, Cornelissen JJ, et al. Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON). Eur J Cancer. 2013;49(15):3242-3246.
6. Yhim HY, Lee NR, Song EK, et al. Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response. Leuk Res. 2012;36(6):689-693.
7. Takahashi N, Kyo T, Maeda Y, et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica. 2012;97(6):903-906.
8. Horn M, Glauche I, Muller MC, et al. Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Blood. 2013;121(2):378-384.
9. Mori S, Vagge E, le Coutre P, et al. Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study. Am J Hematol. 2015;90(10):910-914.
10. Richter J, Soderlund S, Lubking A, et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol. 2014;32(25):2821-2823.
11. Park JS, Lee SE, Jeong SH, et al. Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients. Leuk Lymphoma. 2015 Jun 12:1-7. [Epub ahead of print].
12. Goh HG, Lin M, Fukushima T, et al. Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. Leuk Lymphoma. 2011;52(5):896-904.
13. Ross DM, Hughes TP. How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia. Br J Haematol. 2014;166(1):3-11.
14. Breccia M, Alimena G. Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemia. Cancer Lett. 2014; 347(1):22-28.
15. Mahon F-X, Rea D, Guilhot J, et al. Discontinuation of Imatinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Complete Molecular Response: Update Results of the STIM Study. ASH Annual Meeting Abstracts 2011;118(21):603.
16. Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nat Rev Neurosci. 2005;6(7):521-532.
17. Mizoguchi I, Yoshimoto T, Katagiri S, et al. Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib. Cancer Sci. 2013;104(9):1146-1153.
18. Ohyashiki K, Katagiri S, Tauchi T, et al. Increased natural killer cells and decreased CD3(+)CD8(+)CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib. Br J Haematol. 2012;157(2):254-256.
19. Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6(9):1018-1023.
20. Kanodia S, Wieder E, Lu S, et al. PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal. PLoS One. 2010;5(7):e11770.
21. Burchert A, Wolfl S, Schmidt M, et al. Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood. 2003;101(1):259-264.